Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
Status:
Completed
Trial end date:
2019-12-24
Target enrollment:
Participant gender:
Summary
This is an international, multi-center, double-blind, placebo-controlled evaluation
valganciclovir treatment for up to 54 children (up to 4 years of age) with
virologically-confirmed congenital CMV infection and hearing loss. Subject participation will
be over a six-month period and study subjects will be stratified according to age. The
primary objective is to assess whether a six-week course of oral valganciclovir can stabilize
the hearing of children with congenital CMV infection who present with hearing loss.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID) University of Alabama at Birmingham